Fernando Mora

Prof. Dr. Fernando Mora

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
Miguel Angel Alvarez-MonMiguel Angel Alvarez-Mon
Miguel Angel Alvarez-Mon
CGCielo García-Montero
Cielo García-Montero
ÓMÓscar Fraile Martínez
Óscar Fraile Martínez
Luis G GuijarroLuis G Guijarro
Luis G Guijarro
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
The gut microbiota is a complex and dynamic ecosystem essential for the proper functioning of the organism, affecting the health and disease status of the individuals. There is continuous and bidirectional communication between gut microbiota and the host, conforming to a unique entity known as “holobiont”. Among these crosstalk mechanisms, the gut microbiota synthesizes a broad spectrum of bioactive compounds or metabolites which exert pleiotropic effects on the human organism. Many of these microbial metabolites can cross the blood–brain barrier (BBB) or have significant effects on the brain, playing a key role in the so-called microbiota-gut-brain axis. An altered microbiota-gut-brain (MGB) axis is a major characteristic of many neuropsychiatric disorders, including major depressive disorder (MDD). Significative differences between gut eubiosis and dysbiosis in mental disorders like MDD with their different metabolite composition and concentrations are being discussed. In the present review, the main microbial metabolites (short-chain fatty acids -SCFAs-, bile acids, amino acids, tryptophan -trp- derivatives, and more), their signaling pathways and functions will be summarized to explain part of MDD pathophysiology. Conclusions from promising translational approaches related to microbial metabolome will be addressed in more depth to discuss their possible clinical value in the management of MDD patients.

29 December 2021 in Expert Opinion on Drug Safety
Verified
Journal Article
Open access
JDJavier De Diego-Adeliño
Javier De Diego-Adeliño
JCJosé Manuel Crespo
José Manuel Crespo
FMFernando Mora
Fernando Mora
ANAdrián Neyra
Adrián Neyra
PIPedro Iborra
Pedro Iborra
SSSelman F. Salonia
Selman F. Salonia
Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the m...

10 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
Miguel Angel Alvarez-MonMiguel Angel Alvarez-Mon
Miguel Angel Alvarez-Mon
CGCielo García-Montero
Cielo García-Montero
ÓMÓscar Fraile Martínez
Óscar Fraile Martínez
GLGuillermo Lahera
Guillermo Lahera
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Major Depressive Disorder (MDD) represents a major global health concern, a body-mind malady of rising prevalence worldwide nowadays. The complex network of mechanisms involved in MDD pathophysiology is subjected to epigenetic changes modulated by microRNAs (miRNAs). Serum free or vesicles loaded miRNAs have starred numerous publications, denoting a key role in cell-cell communication, systematically and in brain structure and neuronal morphogenesis, activity and plasticity. Upregulated or downregulated expression of these signaling molecules may imply the impairment of genes implicated in pathways of MDD etiopathogenesis (neuroinflammation, brain-derived neurotrophic factor (BDNF), neurotransmitters, hypothalamic-pituitary-adrenal (HPA) axis, oxidative stress, circadian rhythms...). In addition, these miRNAs could serve as potential biomarkers with diagnostic, prognostic and predictive value, allowing to classify severity of the disease or to make decisions in clinical management. They have been considered as promising therapy targets as well and may interfere with available antidepressant treatments. As epigenetic malleable regulators, we also conclude emphasizing lifestyle interventions with physical activity, mindfulness and diet, opening the door to new clinical management considerations.

19 September 2011 in Annals of General Psychiatry
Verified
Journal Article
Open access
PDF file
FCFernando Chacón
Fernando Chacón
FMFernando Mora
Fernando Mora
AGAlicia Gervás-Ríos
Alicia Gervás-Ríos
IGInmaculada Gilaberte
Inmaculada Gilaberte
Awareness of the importance of maintaining physical health for patients with severe mental illnesses has recently been on the increase. Although there are several elements contributing to poor physical health among these patients as compared with the general population, risk factors for cardiovascular disease such as smoking, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and obesity are of particular significance due to their relationship with mortality and morbidity. These patients present higher vulnerability to cardiovascular risk factors based on several issues, such as genetic predisposition to certain pathologies, poor eating habits and sedentary lifestyles, high proportions of smokers and drug abusers, less access to regular health care services, and potential adverse events during pharmacological treatment. Nevertheless, there is ample scientific evidence supporting the benefits of lifestyle interventions based on diet and exercise designed to minimize and reduce the negative impact of these risk factors on the physical health of patients with severe mental illnesses.

6 March 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
CGCielo García-Montero
Cielo García-Montero
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
Miguel Angel Alvarez-MonMiguel Angel Alvarez-Mon
Miguel Angel Alvarez-Mon
ÓMÓscar Fraile Martínez
Óscar Fraile Martínez
Adoracion Romero-BazánAdoracion Romero-Bazán
Adoracion Romero-Bazán
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Major depressive disorder (MDD) is an incapacitating condition characterized by loss of interest, anhedonia and low mood, which affects almost 4% of people worldwide. With rising prevalence, it is considered a public health issue that affects economic productivity and heavily increases health costs alone or as a comorbidity for other pandemic non-communicable diseases (such as obesity, cardiovascular disease, diabetes, inflammatory bowel diseases, etc.). What is even more noteworthy is the double number of women suffering from MDD compared to men. In fact, this sex-related ratio has been contemplated since men and women have different sexual hormone oscillations, where women meet significant changes depending on the age range and moment of life (menstruation, premenstruation, pregnancy, postpartum, menopause…), which seem to be associated with susceptibility to depressive symptoms. For instance, a decreased estrogen level promotes decreased activation of serotonin transporters. Nevertheless, sexual hormones are not the only triggers that alter neurotransmission of monoamines and other neuropeptides. Actually, different dietary habits and/or nutritional requirements for specific moments of life severely affect MDD pathophysiology in women. In this context, the present review aims to descriptively collect information regarding the role of malnutrition in MDD onset and course, focusing on female patient and especially macro- and micronutrient deficiencies (amino acids, ω3 polyunsaturated fatty acids (ω3 PUFAs), folate, vitamin B12, vitamin D, minerals…), besides providing evidence for future nutritional intervention programs with a sex-gender perspective that hopefully improves mental health and quality of life in women.

21 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Miguel Angel Alvarez-MonMiguel Angel Alvarez-Mon
Miguel Angel Alvarez-Mon
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
CGCielo García-Montero
Cielo García-Montero
ÓMÓscar Fraile Martínez
Óscar Fraile Martínez
Jorge Monserrat SanzJorge Monserrat Sanz
Jorge Monserrat Sanz
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Major depressive disorder (MDD) is a complex and common disorder, with many factors involved in its onset and development. The clinical management of this condition is frequently based on the use of some pharmacological antidepressant agents, together with psychotherapy and other alternatives in most severe cases. However, an important percentage of depressed patients fail to respond to the use of conventional therapies. This has created the urgency of finding novel approaches to help in the clinical management of those individuals. Nutraceuticals are natural compounds contained in food with proven benefits either in health promotion or disease prevention and therapy. A growing interest and economical sources are being placed in the development and understanding of multiple nutraceutical products. Here, we summarize some of the most relevant nutraceutical agents evaluated in preclinical and clinical models of depression. In addition, we will also explore less frequent but interest nutraceutical products which are starting to be tested, also evaluating future roads to cover in order to maximize the benefits of nutraceuticals in MDD.